AMNEAL PHARMACEUTICALS INC (AMRX) Stock Price, Quote, News and Overview
NASDAQ:AMRX - Nasdaq - US03168L1052 - Common Stock - Currency: USD
AMRX Quote, Performance and Key Statistics
AMNEAL PHARMACEUTICALS INC
NASDAQ:AMRX (1/24/2025, 5:20:00 PM)
After market: 8.68 0 (0%)8.68
-0.13 (-1.48%)
The current stock price of AMRX is 8.68 USD. In the past month the price increased by 11.42%. In the past year, price increased by 58.11%.
AMRX Latest News, Press Releases and Analysis
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.
Amneal to Participate at Upcoming Investor Conferences
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Amneal Reports Third Quarter 2024 Financial Results
AMRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 77.23 | 745.61B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.62 | 390.70B | ||
| JNJ | JOHNSON & JOHNSON | 14.7 | 353.49B | ||
| MRK | MERCK & CO. INC. | 16.06 | 241.71B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.13 | 214.16B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.4 | 199.87B | ||
| PFE | PFIZER INC | 10.11 | 147.85B | ||
| SNY | SANOFI-ADR | 12.56 | 131.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51 | 121.02B | ||
| ZTS | ZOETIS INC | 29.27 | 76.07B | ||
| GSK | GSK PLC-SPON ADR | 8.34 | 69.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.65 | 41.18B |
Related stock screener links
About AMRX
Company Profile
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 7,700 full-time employees. The company went IPO on 2009-11-18. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Company Info
AMNEAL PHARMACEUTICALS INC
400 Crossing Boulevard, 3rd Floor
Bridgewater NEW JERSEY 08807 US
CEO: Chirag Patel
Employees: 7850
Company Website: https://amneal.com/
Investor Relations: http://investors.amneal.com/investor-relations/default.aspx
Phone: 19089473120
AMRX FAQ
What is the stock price of AMRX?
The current stock price of AMRX is 8.68 USD.
What is the symbol for AMNEAL PHARMACEUTICALS INC stock?
The exchange symbol of AMNEAL PHARMACEUTICALS INC is AMRX and it is listed on the Nasdaq exchange.
On which exchange is AMRX stock listed?
AMRX stock is listed on the Nasdaq exchange.
Is AMRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AMRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AMRX.
Does AMRX stock pay dividends?
AMRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of AMRX?
The PE ratio for AMRX is 14.47. This is based on the reported non-GAAP earnings per share of 0.6 and the current share price of 8.68 USD.
What is the Short Interest ratio of AMRX stock?
The outstanding short interest for AMRX is 2.43% of its float.
AMRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AMRX. When comparing the yearly performance of all stocks, AMRX is one of the better performing stocks in the market, outperforming 86.81% of all stocks.
AMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMRX. There are concerns on the financial health of AMRX while its profitability can be described as average.
AMRX Financial Highlights
Over the last trailing twelve months AMRX reported a non-GAAP Earnings per Share(EPS) of 0.6. The EPS increased by -17.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.42% | ||
| ROE | -424.61% | ||
| Debt/Equity | 134.73 |
AMRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to AMRX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 23.68% and a revenue growth 3.9% for AMRX